Literature DB >> 15472191

Endogenous levels of serum estradiol and sex hormone binding globulin determine bone mineral density, bone remodeling, the rate of bone loss, and response to treatment with estrogen in elderly women.

Prema B Rapuri1, J Christopher Gallagher, Gleb Haynatzki.   

Abstract

A total of 489 elderly women aged 65-75 yr who participated in a 3-yr, randomized, blinded osteoporosis trial underwent measurements of serum estradiol, bioavailable estradiol, and SHBG. At baseline, bone mineral density (BMD) was lower at the femoral sites (7-19%, P < 0.05), total body (6-8%, P < 0.05), and spine (5-9%, P = 0.2) in women in the lowest tertile for serum total estradiol [<9 pg/ml (33 pmol/liter)], serum bioavailable estradiol [<2.4 pg/ml (8.8 pmol/liter)], or highest tertile for serum SHBG (>165 nmol/liter), compared with women in the highest tertiles of total estradiol [>13.3 pg/ml (49 pmol/liter)] and bioavailable estradiol [>4 pg/ml (14 pmol/liter)] or lowest tertile for SHBG (<113 nmol/liter). Bone markers were increased in women in the lowest tertile for serum total estradiol (not significant) and bioavailable estradiol (P < 0.05) and highest tertile for SHBG (P < 0.05). In the longitudinal study, the rate of bone loss in the placebo group was significantly higher in total body (P < 0.05) and spine (P < 0.05) in women in the lowest tertile, compared with the highest tertile of serum bioavailable estradiol. After treatment with conjugated equine estrogens 0.625 mg/d, the increase in BMD was 4-6% higher at the femoral sites (P < 0.05), total body (P < 0.05), and spine (not significant), in the lowest tertile, compared with the highest tertile of serum bioavailable estradiol or highest tertile, compared with the lowest tertile of serum SHBG. In summary, small variations in endogenous serum estradiol and high serum SHBG determine differences in BMD and rate of bone loss in elderly women and also affect the response to treatment with estrogen. Women with a serum estradiol level of less than 9 pg/ml (33 pmol/liter) are optimal candidates for estrogen therapy for osteoporosis prevention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15472191     DOI: 10.1210/jc.2004-0434

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

1.  Lean body mass, not estrogen or progesterone, predicts peak bone mineral density in premenopausal women.

Authors:  Lee-Jane W Lu; Fatima Nayeem; Karl E Anderson; James J Grady; Manubai Nagamani
Journal:  J Nutr       Date:  2008-12-23       Impact factor: 4.798

Review 2.  Prevention and treatment of postmenopausal osteoporosis.

Authors:  Sri Harsha Tella; J Christopher Gallagher
Journal:  J Steroid Biochem Mol Biol       Date:  2013-10-29       Impact factor: 4.292

3.  Genetically Predicted Sex Hormone-Binding Globulin and Bone Mineral Density: A Mendelian Randomization Study.

Authors:  Zihao Qu; Jiuzhou Jiang; Fangkun Yang; Jiawei Huang; Jianqiang Zhao; Shigui Yan
Journal:  Calcif Tissue Int       Date:  2020-10-17       Impact factor: 4.333

4.  Association of serum 17β-estradiol concentration, hormone therapy, and alveolar crest height in postmenopausal women.

Authors:  Youjin Wang; Michael J LaMonte; Kathleen M Hovey; Xiaodan Mai; Mine Tezal; Amy E Millen; Heather M Ochs-Balcom; Robert J Genco; Vanessa M Barnabei; Jean Wactawski-Wende
Journal:  J Periodontol       Date:  2015-01-16       Impact factor: 6.993

5.  Genetic influence on the association between bone mineral density and testosterone in Korean men.

Authors:  J Shin; J Sung; K Lee; Y-M Song
Journal:  Osteoporos Int       Date:  2015-09-02       Impact factor: 4.507

6.  Stereochemical effects during [M-H]- dissociations of epimeric 11-OH-17beta-estradiols and distant electronic effects of substituents at C(11) position on gas phase acidity.

Authors:  Sandrine Bourgoin-Voillard; Emilie-Laure Zins; Françoise Fournier; Yves Jacquot; Carlos Afonso; Claude Pèpe; Guy Leclercq; Jean-Claude Tabet
Journal:  J Am Soc Mass Spectrom       Date:  2009-09-03       Impact factor: 3.109

7.  Bone mineral density and its determinants in diabetes: the Fremantle Diabetes Study.

Authors:  V Rakic; W A Davis; S A P Chubb; F M A Islam; R L Prince; T M E Davis
Journal:  Diabetologia       Date:  2006-03-04       Impact factor: 10.122

8.  Baseline serum estradiol and fracture reduction during treatment with hormone therapy: the Women's Health Initiative randomized trial.

Authors:  J A Cauley; A Z LaCroix; J A Robbins; J Larson; R Wallace; J Wactawski-Wende; Z Chen; D C Bauer; S R Cummings; R Jackson
Journal:  Osteoporos Int       Date:  2009-05-13       Impact factor: 4.507

9.  Role of Sandhika: a polyherbal formulation on MC3T3-E1 osteoblast-like cells.

Authors:  Yamini B Tripathi; Pratibha Tripathi; Kiranmayi Korlagunta; Sheau Ching Chai; Brenda J Smith; Bahram H Arjmandi
Journal:  Inflammation       Date:  2008-02       Impact factor: 4.092

10.  Associations of serum sex hormone binding globulin with bone mineral densities and higher 10-year probability of fractures in postmenopausal women with type 2 diabetes mellitus.

Authors:  Yixuan Jing; Xiaofeng Wang; Jingjia Yu; Xiaojing Wang; Yanman Zhou; Bei Tao; Lihao Sun; Jianmin Liu; Hongyan Zhao
Journal:  Ann Transl Med       Date:  2019-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.